Alcohol addiction: toward a patient-oriented pharmacological treatment

Very few medications (i.e., disulfiram, naltrexone and acamprosate) are approved for the treatment of alcoholism and their effects are suboptimal. The development of new effective and safe pharmacological agents to treat alcoholic patients is crucial, together with the need to identify predictors of outcomes in different subsets of patients.

[1]  J. Blodgett,et al.  The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis. , 2013, Alcoholism, clinical and experimental research.

[2]  G. Addolorato,et al.  Management of Alcohol Dependence in Patients with Liver Disease , 2013, CNS Drugs.

[3]  J. McGeary,et al.  A human laboratory pilot study with baclofen in alcoholic individuals , 2013, Pharmacology Biochemistry and Behavior.

[4]  G. Addolorato,et al.  Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. , 2012, Addictive behaviors.

[5]  S. Cichon,et al.  Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate , 2011, The Pharmacogenomics Journal.

[6]  Ming D. Li,et al.  Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. , 2011, The American journal of psychiatry.

[7]  R. Gallop,et al.  Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. , 2010, Alcoholism, clinical and experimental research.

[8]  G. Addolorato,et al.  Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. , 2010, Current pharmaceutical design.

[9]  J. McGeary,et al.  A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. , 2009, Alcoholism, clinical and experimental research.

[10]  D. Couper,et al.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. , 2008, Archives of general psychiatry.

[11]  G. Gasbarrini,et al.  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study , 2007, The Lancet.

[12]  C. Otte,et al.  Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome , 2005, European Addiction Research.

[13]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[14]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[15]  J. Hensler,et al.  Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. , 2000, JAMA.